8-K: BioNexus Gene Lab Stockholders Approve Key Proposals

BioNexus Gene Lab Corp. stockholders approved the election of directors, a 2025 Equity Incentive Plan, and the independent auditor at their Annual Meeting.

Summary

• The 2025 Annual Meeting of Stockholders was held on December 24, 2025.
• Four nominees, Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, Jook Yuen Low, and Chee Keong Yap, were elected to serve as directors until the next annual meeting.
• The 2025 Equity Incentive Plan was approved with 966,759.8 votes for, 10,628.5 against, and 300 abstentions.
• The appointment of JP Centurion & Partners PLT as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 973,284.3 votes for, 3,402.5 against, and 1,001.5 abstentions.
• A proposal to approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies was also approved.

Sentiment

Score: 7

Explanation: The sentiment is positive as all proposals, including director elections and the equity incentive plan, were approved, indicating stable corporate governance and a commitment to employee incentives.

Positives

• All four director nominees were successfully elected, ensuring continuity in leadership.
• The 2025 Equity Incentive Plan was approved, which can help attract and retain talent by providing equity-based compensation.
• The ratification of JP Centurion & Partners PLT as the independent auditor provides assurance of continued financial oversight and compliance.

Future Outlook

The approval of the 2025 Equity Incentive Plan suggests a forward-looking strategy to incentivize and retain key personnel, potentially supporting future growth and performance.

Management Comments

• The report was signed by Su-Leng Tan Lee, Chief Executive Officer of BioNexus Gene Lab Corp.

Industry Context

This filing reflects standard corporate governance practices for a publicly traded company in the biotechnology or gene lab sector, ensuring board oversight and proper financial auditing, which are critical for investor confidence in a research-intensive industry.

Corporate Governance

Stakeholder Impact

• Shareholders approved key corporate governance proposals, including the election of directors and an equity incentive plan.
• Employees may benefit from the newly approved 2025 Equity Incentive Plan, which provides opportunities for equity compensation.

Next Steps

• The elected directors will hold office until the Company's next annual meeting of stockholders or until their successors are duly elected and qualified.
• The 2025 Equity Incentive Plan will be implemented.
• JP Centurion & Partners PLT will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

BioNexus Gene Lab Corp, BGLC, Annual Meeting, Stockholders, Director Election, Equity Incentive Plan, Auditor Ratification, Corporate Governance, SEC Filing, 8-K